Indication
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor or whose disease has progressed after prior treatment with an ALK inhibitor.
Medicine details
- Medicine name:
- lorlatinib (Lorviqua)
- SMC ID:
- SMC2867
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Reassessment
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 01 June 2026